EMPLOYMENT AGREEMENTEmployment Agreement • November 3rd, 2011 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New Jersey
This EMPLOYMENT AGREEMENT (this "Agreement") is entered into as of September 9, 2011, by and between NPS PHARMACEUTICALS, INC., a Delaware corporation, with a business address at 550 Hills Drive, Bedminster, New Jersey 07921, and all its affiliates (collectively the "Company"), and Eric Pauwels, with an address of 5 Farrington Lane, Hamilton MA, 01982 (the "Executive").
FIRST AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • November 3rd, 2011 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
THIS FIRST AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT (the "Amendment") is dated as of November 19, 2004, which Amendment shall become effective as of the effective date of that certain Second Amendment to the Agreement (as defined below) (the "Effective Date"), by and between NPS Pharmaceuticals, Inc. ("NPS") and Amgen Inc. ("Amgen"). NPS and Amgen are referred to in this Amendment individually as a "Party" and collectively as the "Parties."
SECOND AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • November 3rd, 2011 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
THIS SECOND AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT (the "Second Amendment") is made and entered into on November 19, 2004 (the "Second Amendment Effective Date"), by and between NPS Pharmaceuticals, Inc. ("NPS") and Amgen Inc. ("Amgen"). NPS and Amgen are referred to in this Second Amendment individually as a "Party" and collectively as the "Parties."
THIRD AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • November 3rd, 2011 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
This THIRD AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT (the "Thtrd Amendment") is made and entered into on March 4, 2008 (the "Third Amendment Effective Date"), by and between NPS Pharmaceuticals, Inc. ("NPS") and Amgen Inc. ("Amgen"). NPS and Amgen are referred to in this Third Amendment individually as a "Party" and collectively as the "Parties".
EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN GLAXOSMITHKLINE LLC AND NPS PHARMACEUTICALS, INC.Exclusive Patent License Agreement • November 3rd, 2011 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
THIS EXCLUSIVE PATENT LICENSE AGREEMENT ("Agreement"), is entered into as of July 29, 2011 (the "Effective Date") by and between GlaxoSmithKline LLC, a Delaware limited liability company with an address at One Franklin Plaza, Philadelphia, Pennsylvania 19106 (formerly known as SmithKline Beecham Corporation) ("GSK"), and NPS Pharmaceuticals, Inc., a Delaware corporation with an address at 550 Hills Dr., 3rd Floor, Bedminster, New Jersey 07921 ("NPS"). GSK and NPS are referred to in this Agreement each individually as a "Party" and collectively as the "Parties".
NOTE: CERTAIN CONFIDENTIAL INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT AND REPLACED BY "[*]". A COMPLETE COPY OF THIS DOCUMENT INCLUDING THE CONFIDENTIAL INFORMATION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.Manufacturing Agreement • November 3rd, 2011 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS MANUFACTURING AGREEMENT (the "Agreement") is made and entered into with an effective date of August 1, 2009 ("Effective Date"), by and between:
